GLP-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES

Incorporating the Latest Treatment Options Into Individualized Care

Start Date: 10/8/2020 End Date: 02/28/2022

Target Audience: This CE program was developed for NPs who see patients with T2D in primary care settings who must understand the pharmacokinetics and pharmacodynamics, benefits and risks of the latest available agents for treatment of T2D.

Program Delivery: 3 Live Webinars, 1 Enduring

Activity Description: Nearly 80% of the more than 31.1 people in the U.S. with T2D are reportedly uncontrolled. NPs must be able to explain the serious nature of T2D, address adherence issues leading to suboptimal blood glucose levels and select the best available treatments to reduce the development of long-term complications.

Learning Objectives:

- Describe the short- and long-term adverse outcomes of elevated HbA1c levels.
- Appraise the importance of the regular assessment of HbA1c levels and the modification of treatment for patients who are not meeting goals.
- Diagram treatment plans for the rapid attainment of HbA1c targets.
- Prioritize factors associated with a patient-centered approach for T2D management, including cardiovascular comorbidities, risk for hypoglycemia and patient preferences.
- Explain individualized and evidence-based strategies to overcome barriers to T2D pharmacotherapy adherence.

Participation

Based on learner evaluations received

(n=3,157)

Registrations: 9,681

Starts: 2,648

Completions: 3,938 of whom 3,157 see

patients with T2D

Certification

NP	Diabetes Educator	Other
97.8% (3,086)	1.4% (45)	0.8% (26)

Patient Focus

Primary/Family	Endocrine Specialty	Other
69.4% (2,191)	6.3% (198)	24.3% (768)

Practice Setting*

Clinic	Hospital	Other
77.6% (2,449)	11.8% (372)	10.6% (336)



1.25 contact hour(s) of CE which included 1.25 hour(s) of pharmacology) by AANP.

Supported by an independent educational grant from Novo Nordisk

Faculty




Dixie Harms, DNP, ARNP, FNP-C, BC-**ADM, FAANP**



Shannon K. Idzik, DNP, CRNP, FAANP, **FAAN**

Activity Impact



66.5% patients impacted **Intend Change** weekly in Practice